It exhibited anti-proliferative and apoptotic effects in prostate cancer cells by downregulating the master drivers AR-V7 (an activated AR variant that lacks the C-terminal binding domain) and PSA (a gene targeted by AR) in both castration-resistant and sensitive prostate cancers when tested in vitro [25]. This evidence concerns the gene AR and prostate carcinoma.